Day: April 30, 2025

VANCOUVER, British Columbia, April 30, 2025 (GLOBE NEWSWIRE) — Christina Lake Cannabis Corp. (the “Company” or “CLC” or “Christina Lake Cannabis”) (CSE: CLC) (OTCQB: CLCFF) (FRANKFURT: CLB) further to the press release dated April 23, 2025, the Company is pleased to announce that it has closed the first tranche (the “First Tranche”) of a non-brokered private placement of units (“Units“), with each Unit consisting of one common share in the capital of the Company (each a “Share”) and one half of one common share purchase warrant (each whole warrant a “Warrant“), in the principal amount of CDN $1,138,910.55 (the “Offering”). The Company issued 22,778,211 Units at a price of $0.05 per Unit under the closing of the first tranche, which were in the form of a debt settlement of principal and accrued interest due...

NBI-1117568 is an oral, muscarinic M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with Neurocrine For more information, please read Neurocrine’s announcement (link)Tokyo, Japan and Cambridge, UK, 1 May 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has initiated a Phase 3 registrational program to evaluate the efficacy, safety and tolerability of NBI-1117568 (NBI-’568), an investigational oral muscarinic M4 selective orthosteric agonist, as a potential treatment for schizophrenia. Positive top-line data for the Phase 2 clinical study in adults with schizophrenia were reported in August 2024. Chris Cargill, President and CEO of Nxera Pharma, commented: “Today’s news...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, April 30, 2025 (GLOBE NEWSWIRE) — Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon Organics” or the “Company”), a licensed producer focused on cultivating and selling organic certified and premium cannabis products, is pleased to announce that due to market demand, the Company has increased the size of its previously announced non-brokered private placement offering under the listed issuer financing exemption (the “Exemption”) under Part 5A of National Instrument 45-106 Prospectus Exemptions (“NI 45-106”) from $3,000,000 to $4,500,000 (the “Offering”). The Offering will consist of up to 10,227,272 units of the Company (each, a “Unit”) at a price of $0.44 per Unit for aggregate gross proceeds...

TORONTO, April 30, 2025 (GLOBE NEWSWIRE) — ABERDEEN INTERNATIONAL INC. (“Aberdeen” or the “Company”) (TSX: AAB, F:A8H, OTC:AABVF) announces today that General (ret’d) Lewis MacKenzie has resigned as a director of the Company. The board and management thank General MacKenzie for his services and extensive contributions and wish him well in his future endeavours. ABOUT ABERDEEN INTERNATIONAL INC. Aberdeen is a global resource investment company and merchant bank focused on small capitalization companies in the rare metals and renewable energy sectors. For further information, please contact: Dev ShettyExecutive Chairman and Chief Executive Officer Aberdeen International Inc. Dev.Shetty@aberdeen.green THE TSX HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OF THIS NEWS RELEASE.

Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatmentof Focal Segmental Glomerulosclerosis (FSGS) DMX-200 is in a pivotal Phase 3 trial for FSGS, a rare and fatal kidney disease with no FDA-approved therapies Dimerix successfully completed Type C meeting with the FDA in March 2025, aligning on proteinuria as the primary endpoint for approval Dimerix to receive US$30 million (~AU$48 million) upfront payment, up to US$560 million (~AU$892 million) for success-based milestone payments, in addition to tiered royalties on DMX-200 net U.S. sales MELBOURNE, Australia and PRINCETON, N.J., April 30, 2025 (GLOBE NEWSWIRE) — Dimerix Limited (ASX: DXB, “Dimerix”) and Amicus Therapeutics (Nasdaq: FOLD, “Amicus”) today announced that the two companies have entered into an exclusive license agreement for the commercialization...

Tokyo, Japan and Cambridge, UK, 1 May 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces the appointment of Shinya Tsuzuki, as Head of Investor Relations. Mr. Tsuzuki will lead Nxera’s Investor Relations (IR) team in Japan and report to the Company’s Chief Financial Officer, Hironoshin Nomura. Mr. Tsuzuki joins Nxera from Mizuho Securities, where he served as a Senior Investment Analyst and has covered the pharmaceutical and biotechnology sector since 2018. During this time, Mr. Tsuzuki was ranked 2nd among pharma and biotech analysts in the Nikkei Veritas rankings in both 2022 and 2023, and 3rd in both 2024 and 2025. He was also ranked 2nd in the Extel rankings, formerly Institutional Investor Biotechnology & Pharmaceuticals category, in both 2022 and 2023, and 4th in both 2024 and 2025. Mr. Tsuzuki...